Clinical Development


Anna van Muyden | Head of Clinical Science Oncology & Program Lead NHL, Galapagos

Anna van Muyden is a clinical development leader with 10 years of experience in the field of hemato-oncology and ATMPs, and is passionate about bringing innovative treatments to patients. In 2019, she joined the Leiden-based biotech start-up CellPoint B.V. as the first hire and Head of Clinical Development, leading the company’s clinical CAR-T programs in hematology. After the successful acquisition by the Dutch-Belgian biotech company Galapagos in 2022, she has continued her career as Head of Clinical Science Oncology. Anna holds a BSc in Biomedical Sciences and an MSc in Science and Business Management from Utrecht University. Previous positions include running clinical trial operations in UMC Utrecht and leading a first-in-human program in the Dutch cancer immunotherapies company Gadeta.



Galapagos

Galapagos is a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders.


Clinical Development

This session delves into the clinical development phase of Life Sciences products and builds on the foundations from the first session, which will cover a broader range of Life Science product development aspects such as finance and IP. Participants will gain insights into the pivotal role of Clinical Development within a life sciences company.

Drawing on experiences from both the start-up environment at CellPoint, where the first-in-human trials were initiated, and the current work at Galapagos, a larger, integrated biotech company, Anna van Muyden will explore the progression through phase 2 and pivotal studies. The session will highlight the challenges encountered and best practices for effectively navigating this critical phase, providing a comprehensive understanding based on real-world trials conducted at Galapagos.

Powered by:
BCF Courses BV   

    Connect with us                  

Join BioBusiness Summer School
Privacy Policy
Terms & Conditions 
Chamber of Commerce: 75874415
         
  
  
  
                                     
        REGISTER NOW
    

© Copyright 2020 by BCF Courses